NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD
NASDAQ:SXTP (5/2/2025, 4:12:28 PM)
2.28
-0.2 (-8.06%)
The current stock price of SXTP is 2.28 USD. In the past month the price increased by 31.91%. In the past year, price decreased by -80.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
JNJ | JOHNSON & JOHNSON | 15.53 | 376.23B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
PFE | PFIZER INC | 7.54 | 137.25B | ||
SNY | SANOFI-ADR | 14.36 | 135.72B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
ZTS | ZOETIS INC | 26.59 | 70.23B | ||
HLN | HALEON PLC-ADR | 21.84 | 48.28B |
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Company Website: https://60degreespharma.com/
Investor Relations: https://investors.60degreespharma.com/
Phone: 12023275422
The current stock price of SXTP is 2.28 USD. The price decreased by -8.06% in the last trading session.
The exchange symbol of 60 DEGREES PHARMA INC is SXTP and it is listed on the Nasdaq exchange.
SXTP stock is listed on the Nasdaq exchange.
8 analysts have analysed SXTP and the average price target is 5.92 USD. This implies a price increase of 159.47% is expected in the next year compared to the current price of 2.28. Check the 60 DEGREES PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
60 DEGREES PHARMA INC (SXTP) has a market capitalization of 3.35M USD. This makes SXTP a Nano Cap stock.
60 DEGREES PHARMA INC (SXTP) currently has 3 employees.
60 DEGREES PHARMA INC (SXTP) has a support level at 2.06 and a resistance level at 2.82. Check the full technical report for a detailed analysis of SXTP support and resistance levels.
The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 109.78% in the next year. Check the estimates tab for more information on the SXTP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SXTP does not pay a dividend.
60 DEGREES PHARMA INC (SXTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.64).
The outstanding short interest for 60 DEGREES PHARMA INC (SXTP) is 30.26% of its float. Check the ownership tab for more information on the SXTP short interest.
ChartMill assigns a technical rating of 2 / 10 to SXTP. When comparing the yearly performance of all stocks, SXTP is a bad performer in the overall market: 95.1% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. Both the profitability and financial health of SXTP have multiple concerns.
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -39.64. The EPS decreased by -801.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -146.38% | ||
ROE | -208.9% | ||
Debt/Equity | 0.04 |
ChartMill assigns a Buy % Consensus number of 80% to SXTP. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 90.39% and a revenue growth 109.78% for SXTP